ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
35.71
-0.56%
US Tech 100
18,307.60
0.41%
S&P 500
5,307.01
-0.27%
US Dollar vs CAD
1.36845
-0.05%
Bitcoin
69,289.35
0.28%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Edgewise Therapeutics Inc (EWTX)

  7. Edgewise Therapeutics Inc (EWTX) News

EWTX

Edgewise Therapeutics (EWTX)

Edgewise Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:EWTX
DateTimeSourceHeadlineSymbolCompany
05/10/20248:10AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:EWTXEdgewise Therapeutics Inc
05/10/20248:07AMEdgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:EWTXEdgewise Therapeutics Inc
05/10/20247:00AMBusiness WireEdgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 15, 2024NASDAQ:EWTXEdgewise Therapeutics Inc
05/09/20248:21AMEdgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:EWTXEdgewise Therapeutics Inc
05/09/20247:06AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:EWTXEdgewise Therapeutics Inc
05/09/20247:00AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:EWTXEdgewise Therapeutics Inc
05/09/20247:00AMBusiness WireEdgewise Therapeutics Reports First Quarter 2024 Financial Results and Recent Business HighlightsNASDAQ:EWTXEdgewise Therapeutics Inc
05/07/20248:16AMEdgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:EWTXEdgewise Therapeutics Inc
05/07/20248:14AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:EWTXEdgewise Therapeutics Inc
05/07/20247:00AMBusiness WireEdgewise Therapeutics Appoints Arlene Morris to its Board of DirectorsNASDAQ:EWTXEdgewise Therapeutics Inc
05/06/20247:00AMBusiness WireEdgewise Therapeutics Doses First Patient in Phase 2 CIRRUS-HCM Trial of EDG-7500 in Obstructive Hypertrophic Cardiomyopathy (HCM)NASDAQ:EWTXEdgewise Therapeutics Inc
04/23/20247:00AMBusiness WireEdgewise Receives European Medicines Agency (EMA) Orphan Drug Designations for Sevasemten (EDG-5506) for the Treatment of Becker and Duchenne Muscular DystrophiesNASDAQ:EWTXEdgewise Therapeutics Inc
04/15/20243:05PMBusiness WireEdgewise Therapeutics Announces Positive Two-Year Topline Results from the ARCH Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy (Becker)NASDAQ:EWTXEdgewise Therapeutics Inc
03/28/20247:00AMBusiness WireEdgewise Therapeutics Announces Upcoming Podium Presentation at the American College of Cardiology's 2024 Annual Scientific SessionNASDAQ:EWTXEdgewise Therapeutics Inc
03/27/20247:00AMBusiness WireEdgewise Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium on April 2, 2024NASDAQ:EWTXEdgewise Therapeutics Inc
03/05/20247:00AMBusiness WireEdgewise Therapeutics to Present at the Leerink Partners Global Biopharma Conference on March 11, 2024NASDAQ:EWTXEdgewise Therapeutics Inc
02/28/20247:00AMBusiness WireEdgewise Therapeutics to Present on EDG-5506 for the Treatment of Becker Muscular Dystrophy at the 2024 MDA Clinical and Scientific ConferenceNASDAQ:EWTXEdgewise Therapeutics Inc
02/22/20247:07AMEdgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:EWTXEdgewise Therapeutics Inc
02/22/20247:07AMEdgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:EWTXEdgewise Therapeutics Inc
02/22/20247:00AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:EWTXEdgewise Therapeutics Inc
02/22/20247:00AMBusiness WireEdgewise Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business HighlightsNASDAQ:EWTXEdgewise Therapeutics Inc
02/14/20247:43AMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:EWTXEdgewise Therapeutics Inc
02/13/20247:00AMBusiness WireEdgewise Receives U.S. FDA Fast Track Designation for EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (Duchenne)NASDAQ:EWTXEdgewise Therapeutics Inc
02/09/20244:42PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EWTXEdgewise Therapeutics Inc
02/07/20243:15PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:EWTXEdgewise Therapeutics Inc
01/19/20243:54PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:EWTXEdgewise Therapeutics Inc
01/19/20247:44AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:EWTXEdgewise Therapeutics Inc
01/19/20247:37AMBusiness WireEdgewise Therapeutics Announces Pricing of $240 Million Underwritten Offering of Common StockNASDAQ:EWTXEdgewise Therapeutics Inc
01/19/20245:05AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:EWTXEdgewise Therapeutics Inc
01/19/20245:04AMEdgar (US Regulatory)Form S-3MEF - Registration adding securities to prior Form S-3 registration [Rule 462(b)]NASDAQ:EWTXEdgewise Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:EWTX

Your Recent History

BIT
P1W577
NLBNPIT1W577 20240621 380
LSE
EVM7
Virgin Med Fin
BIT
P201J0
NLBNPIT201J0 20351221 9....
Delayed Upgrade Clock
ADVFN Logo

Canada
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved